Clinical Trial Detail

NCT ID NCT03264404
Title Azacitidine and Pembrolizumab in Pancreatic Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Columbia University
Indications

pancreatic ductal adenocarcinoma

Therapies

Azacitidine + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.